UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041513
Receipt number R000047391
Scientific Title A new perioperative glucocorticosteroid replacement therapy for cushing syndrome
Date of disclosure of the study information 2020/09/01
Last modified on 2020/08/21 22:37:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A new perioperative glucocorticosteroid replacement therapy for cushing syndrome

Acronym

A perioperative glucocorticosteroid replacement therapy for cushing syndrome

Scientific Title

A new perioperative glucocorticosteroid replacement therapy for cushing syndrome

Scientific Title:Acronym

A perioperative glucocorticosteroid replacement therapy

Region

Asia(except Japan)


Condition

Condition

Perioperative

Classification by specialty

Medicine in general Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safty and effects of a new perioperative glucocorticosteroid replacement therapy for Cushing,s syndrome.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Adrenal insufficiency and steroid withdrawal syndrome were not occurred with all patients. Compared with the concentration of urine cortisol preoperation, it was significantly decreased on the day 7 postoperative. Plasma cortisol concentration was significantly decreased on the day 6 postoperative compared with preoperative. All the patients were followed up to 6 months,plasma cortisol and 24h urine cortisol levels were all normal.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Hydrocortisone was given during adrenal resection by intravenous injectionon the surgical day.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

22 years-old <=

Age-upper limit

61 years-old >=

Gender

Male and Female

Key inclusion criteria

The patients who accepted adrenal gland surgery were included in this study.

Key exclusion criteria

The patients who had unilateral or bilateral adrenal tumor or nodule but not accepted adrenal gland surgery were excluded in this study.

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Liang
Middle name
Last name Wang

Organization

Tianjin Medical University General Hospital

Division name

Deprtment of Urology

Zip code

300052

Address

NO 154, Anshan Road, He Ping District, Tianjin, China

TEL

+8615900209758

Email

aliangws@163.com


Public contact

Name of contact person

1st name Liang
Middle name
Last name Wang

Organization

Tianjin Medical University General Hospital

Division name

Deprtment of Urology

Zip code

300052

Address

NO 154, Anshan Road, He Ping District, Tianjin, China

TEL

+8615900209758

Homepage URL


Email

aliangws@163.com


Sponsor or person

Institute

Tianjin Medical University General Hospital

Institute

Department

Personal name



Funding Source

Organization

Tianjin Medical University General Hospital

Organization

Division

Category of Funding Organization

Outside Japan

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tianjin Medical University General Hospital

Address

NO 154, Anshan Road, He Ping District, Tianjin, China

Tel

+8615900209758

Email

aliangws@163.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 09 Month 01 Day


Related information

URL releasing protocol

With all patients, the cortisol circadian rhythm disappeared; Low-dose dexamethasone suppression tes

Publication of results

Unpublished


Result

URL related to results and publications

ResMan Clinical Trial Management Public Platform

Number of participants that the trial has enrolled

83

Results

Adrenal insufficiency and steroid withdrawal syndrome were not occurred with all patients. Compared with the concentration of urine cortisol preoperation, it was significantly decreased on the day 7 postoperative. Plasma cortisol concentration was significantly decreased on the day 6 postoperative compared with preoperative. All the patients were followed up to 6 months,plasma cortisol and 24h urine cortisol levels were all normal.

Results date posted

2020 Year 08 Month 21 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

The age of these patients are ranged from 22 to 61 and the median age is 33. The course of disease is from 1.5 months to 51 months. Seventy eight patients were diagnosed as adrenal adenoma and 5 patients were diagnosed as ACTH independent macronodular adrenal hyperplasia. All the patients had different degree of centripetal obesity, moon face, sanguine temperament looks, skin purple striae and other typical signs of CS.

Participant flow

From July 2014 to July 2017, 83 CS patientswho were referred to our hospital for adrenal gland surgery were considered for this study. We reviewed the computerized database of the patients.

Adverse events

No

Outcome measures

All the patients had a successful operation. The symptoms of adrenal insufficiency includingweakness, fatigue, anorexia, weight loss, nausea and vomiting were not observed. Mortality was zero. Plasma cortisol and 24h urine cortisol levels were measured on the day 1, 2, 6, and 7 postoperative during hospitalization, respectively. Compared with preoperative, plasma cortisol levels on the day 1 and 2 postoperative slightly decreased but no statistical significance; Urine cortisol levels significantly rised (P < 0.05 ) respectively on the day 1 and 2 postoperative, and decreased on the day 6 postoperative to a level slightly lower than the levels of preoperative.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2014 Year 07 Month 01 Day

Date of IRB

2014 Year 07 Month 01 Day

Anticipated trial start date

2014 Year 07 Month 01 Day

Last follow-up date

2017 Year 07 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 08 Month 21 Day

Last modified on

2020 Year 08 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047391


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name